Part 3/6:
The most telling sign of this shift is Soros’ purchase of the IBB, the NASDAQ Biotechnology Index ETF. While this could be perceived as a strategic move to gain exposure to a wide array of biotech stocks—190 to be exact—it might also indicate a retreat from the specific bets he typically makes. Harjes questions whether this shift represents an admission of defeat, speculating that Soros, recognizing the current state of the biotech sector, may have opted to play it safe by investing in the index rather than individual stocks.